Bruce G. Allen Investments, LLC
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 2005409
DENVER, CO
Position in REGN
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$19,329
-$6,168 QoQ
Shares Held
31
-6.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#1,181
of 1,322 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Bruce G. Allen Investments, LLC holds $50,225 across 10 Biotechnology names. REGN ranks #1 (38.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
This page
|
31 | $19,329 | |
| 2 | RPRX |
Royalty Pharma plc
|
178 | $9,980 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15 | $7,450 | |
| 4 | MRNA |
Moderna, Inc.
|
72 | $5,042 | |
| 5 | INCY |
Incyte Corp
|
22 | $2,493 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
23 | $1,823 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
8 | $1,498 | |
| 8 | 39 | $1,225 |
All Filings in REGN
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,329 | 31 | Shares | Sole | 2026-07-31 | |
| 2026-03-31 | $25,497 | 33 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $25,471 | 33 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $17,992 | 32 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $18,900 | 36 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $25,369 | 40 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $32,767 | 46 | Shares | Sole | 2025-01-10 | |
| 2024-09-30 | $34,690 | 33 | Shares | Sole | 2024-10-08 | |
| 2024-06-30 | $44,143 | 42 | Shares | Sole | 2024-07-12 | |
| 2024-03-31 | $35,612 | 37 | Shares | Sole | 2024-04-10 | |
| 2023-12-31 | $39,523 | 45 | Shares | Sole | 2024-01-11 | |
| No filing history on record for this holder in this stock. | ||||||